[EirGenix] The company's biosimilar drug "EIRGASUN vial 420 mg" approved by the NHIA for National Health Insurance coverage
EirGenix's biosimilar drug EIRGASUN (for breast and stomach cancer) has been approved for NHI coverage at NT$24,240 per vial, effective June 1.
📋 Article Processing Timeline
- 📰 Published: May 15, 2026 at 09:00
- 🔍 Collected: May 16, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 16, 2026 at 08:44 (44 min after Collected)
1. Date of occurrence of the event: 115/05/15
2. Company name: EirGenix, Inc.
3. Relationship to the Company (please enter "the company" or "subsidiary"): The company
4. Reciprocal shareholding ratio: Not applicable
5. Cause of occurrence:
(1) The company's biosimilar drug "EIRGASUN vial 420 mg", used to treat HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic stomach cancer, has been approved by the National Health Insurance Administration, Ministry of Health and Welfare for inclusion in National Health Insurance coverage. The approved reimbursement price is NT$24,240 per vial, effective from June 1, Year 115.
(2) According to the Year 113 medical claim data published by the NHIA, the total annual claimed volume for Trastuzumab 420mg to 440mg specifications reached 30,942 vials.
6. Countermeasures: Issue a material information announcement.
7. Other matters to be specified: None
2. Company name: EirGenix, Inc.
3. Relationship to the Company (please enter "the company" or "subsidiary"): The company
4. Reciprocal shareholding ratio: Not applicable
5. Cause of occurrence:
(1) The company's biosimilar drug "EIRGASUN vial 420 mg", used to treat HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic stomach cancer, has been approved by the National Health Insurance Administration, Ministry of Health and Welfare for inclusion in National Health Insurance coverage. The approved reimbursement price is NT$24,240 per vial, effective from June 1, Year 115.
(2) According to the Year 113 medical claim data published by the NHIA, the total annual claimed volume for Trastuzumab 420mg to 440mg specifications reached 30,942 vials.
6. Countermeasures: Issue a material information announcement.
7. Other matters to be specified: None